Document Type

Article

Publication Title

Advances in Medical Sciences and Research

Abstract

Lung cancer remains the leading cause of cancer-related mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for most cases. Advances in targeted therapies and immunotherapy have improved outcomes, but their benefit depends on timely molecular characterization. Early next-generation sequencing (NGS), performed at or near diagnosis, is increasingly used to identify actionable alterations and inform first-line and perioperative treatment planning. In this review, we examine the clinical, operational, and economic rationale for early comprehensive NGS in NSCLC. Upfront sequencing can improve diagnostic yield, preserve limited tissue, reduce turnaround time, and help avoid non-matched systemic therapy. Practical implementation strategies include Molecular Tumor Boards, low-input assays, liquid biopsy integration, and selected artificial intelligence-supported workflow tools, as well as emerging applications such as minimal residual disease monitoring. Improving access to testing and integrating it more consistently into routine care will be important to extend the benefits of comprehensive genomic profiling to a broader range of patients with NSCLC.

DOI

10.55578/amsr.2604.003

Publication Date

4-8-2026

Keywords

non-small cell lung cancer, next-generation sequencing, comprehensive genomic profiling, circulating tumor DNA, healthcare economics, molecular tumor board, artificial intelligence, minimal residual disease

Download

Share

COinS